Eledon Pharmaceuticals (ELDN) Competitors $2.74 -0.70 (-20.35%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.85 +0.11 (+4.01%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. CRMD, IMTX, OCS, NUVB, QURE, PHAR, CRON, SION, ANAB, and GHRSShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include CorMedix (CRMD), Immatics (IMTX), Oculis (OCS), Nuvation Bio (NUVB), uniQure (QURE), Pharming Group (PHAR), Cronos Group (CRON), Sionna Therapeutics (SION), AnaptysBio (ANAB), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Its Competitors CorMedix Immatics Oculis Nuvation Bio uniQure Pharming Group Cronos Group Sionna Therapeutics AnaptysBio GH Research Eledon Pharmaceuticals (NASDAQ:ELDN) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Which has higher valuation & earnings, ELDN or CRMD? CorMedix has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$36.18M-$2.10-1.30CorMedix$82.55M8.88-$17.93M$0.2249.14 Is ELDN or CRMD more profitable? CorMedix has a net margin of 20.81% compared to Eledon Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 22.57% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -79.54% -41.62% CorMedix 20.81%22.57%17.02% Which has more volatility and risk, ELDN or CRMD? Eledon Pharmaceuticals has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Do analysts recommend ELDN or CRMD? Eledon Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 264.96%. CorMedix has a consensus target price of $17.14, indicating a potential upside of 58.58%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Do institutionals & insiders hold more shares of ELDN or CRMD? 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer ELDN or CRMD? In the previous week, CorMedix had 7 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 8 mentions for CorMedix and 1 mentions for Eledon Pharmaceuticals. CorMedix's average media sentiment score of 0.85 beat Eledon Pharmaceuticals' score of 0.00 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCorMedix beats Eledon Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$205.99M$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-1.3017.9729.9325.14Price / SalesN/A179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book1.387.238.105.59Net Income-$36.18M-$54.43M$3.26B$265.48M7 Day Performance-18.93%0.22%0.68%1.22%1 Month Performance-19.88%5.59%2.45%0.39%1 Year Performance6.20%9.98%27.72%23.47% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals1.6755 of 5 stars$2.74-20.3%$10.00+265.0%+5.4%$205.99MN/A-1.3010Gap DownHigh Trading VolumeCRMDCorMedix2.6977 of 5 stars$12.37+6.3%$17.14+38.6%+174.4%$789.48M$82.55M56.2330News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastIMTXImmatics2.7931 of 5 stars$6.61+2.0%$14.67+121.9%-42.9%$787.65M$168.65M-38.88260News CoverageUpcoming EarningsOCSOculis3.0289 of 5 stars$17.94+1.4%$35.33+97.0%+57.6%$772.83M$780K-6.802Positive NewsNUVBNuvation Bio2.0264 of 5 stars$2.31+3.6%$7.17+210.2%-18.5%$758.79M$7.87M-0.9860News CoverageQUREuniQure2.6112 of 5 stars$13.77+0.6%$36.55+165.4%+88.9%$751.40M$27.12M-3.51500PHARPharming Group3.0168 of 5 stars$12.25+11.8%$30.00+144.9%+53.8%$750.92M$297.20M-94.23280Positive NewsHigh Trading VolumeCRONCronos Group2.2565 of 5 stars$2.02+3.6%N/A+2.3%$748.42M$117.61M15.54450Earnings ReportGap UpSIONSionna TherapeuticsN/A$17.12+1.2%$38.50+124.9%N/A$746.59MN/A0.0035Positive NewsLockup ExpirationANABAnaptysBio2.4205 of 5 stars$24.23-1.9%$47.13+94.5%-35.4%$725.40M$91.28M-5.00100News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap UpGHRSGH Research2.7555 of 5 stars$13.44-2.2%$32.00+138.1%+13.2%$714.87MN/A-17.0110Positive NewsEarnings Report Related Companies and Tools Related Companies CRMD Competitors IMTX Competitors OCS Competitors NUVB Competitors QURE Competitors PHAR Competitors CRON Competitors SION Competitors ANAB Competitors GHRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
